Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.

Strollo F, Strollo G, Morè M, Magni P, Macchi C, Masini MA, Carucci I, Celotti F, Ruscica M, Gentile S.

Aging Male. 2013 Jun;16(2):33-7. doi: 10.3109/13685538.2013.773305. Epub 2013 Mar 21.

PMID:
23517433
2.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.

5.

Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.

Borst SE, Yarrow JF.

Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1035-42. doi: 10.1152/ajpendo.00111.2015. Epub 2015 Apr 21. Review.

6.

Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism.

Yamaguchi K, Ishikawa T, Chiba K, Fujisawa M.

Andrologia. 2011 Feb;43(1):52-6. doi: 10.1111/j.1439-0272.2009.01015.x. Epub 2010 Dec 19.

PMID:
21219383
7.

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.

Clin Endocrinol (Oxf). 1997 Dec;47(6):727-37.

PMID:
9497881
8.

Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.

Morrison BF, Reid M, Madden W, Burnett AL.

Andrology. 2013 Jul;1(4):576-82. doi: 10.1111/j.2047-2927.2013.00084.x. Epub 2013 Apr 18.

9.

Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.

Raynaud JP, Gardette J, Rollet J, Legros JJ.

BJU Int. 2013 May;111(6):880-90. doi: 10.1111/j.1464-410X.2012.11514.x. Epub 2013 Jan 7.

10.

Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism.

Naharci MI, Pinar M, Bolu E, Olgun A.

Endocr Pract. 2007 Oct;13(6):629-35.

PMID:
17954419
11.

Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.

Yassin DJ, Doros G, Hammerer PG, Yassin AA.

J Sex Med. 2014 Jun;11(6):1567-76. doi: 10.1111/jsm.12523. Epub 2014 Apr 8.

PMID:
24712761
12.

Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism.

Tsujimura A, Miyagawa Y, Okuda H, Yamamoto K, Fukuhara S, Nakayama J, Takao T, Nonomura N, Okuyama A.

Aging Male. 2011 Mar;14(1):76-81. doi: 10.3109/13685538.2010.502268. Epub 2010 Aug 16.

PMID:
20712429
13.

Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism.

Okada K, Yamaguchi K, Chiba K, Miyake H, Fujisawa M.

Aging Male. 2014 Jun;17(2):72-5. doi: 10.3109/13685538.2014.888052. Epub 2014 Feb 17.

PMID:
24533913
14.

Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.

Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM; Study 43203 Investigators..

Eur J Endocrinol. 2009 May;160(5):821-31. doi: 10.1530/EJE-08-0634. Epub 2009 Feb 11.

15.

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group..

J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53.

PMID:
10946892
18.

Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.

Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G.

Aging Male. 2016;19(1):64-9. doi: 10.3109/13685538.2015.1126573. Epub 2016 Jan 8.

PMID:
26742589
19.

Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.

Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A.

J Endocrinol Invest. 2010 Dec;33(11):776-83. doi: 10.3275/6903. Epub 2010 Mar 10.

PMID:
20220293
20.

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).

Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM.

Clin Interv Aging. 2012;7:321-30. doi: 10.2147/CIA.S32036. Epub 2012 Aug 24.

Supplemental Content

Support Center